Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Researchers at George Washington University take a look.
The latest revision recognizes the importance of treatment as prevention.
Here are the HIV treatment news stories with the most views this year.
The integrase inhibitor–based HIV regimen was compared with dolutegravir-based regimens.
A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.
Updating previous, similar findings, researchers have now reported on 96-week data from a pair of ongoing trials.
A late-stage trial randomized people taking a stable HIV regimen to switch to Dovato or stay on their current antiretrovirals.
The Food and Drug Administration has approved a new treatment for people living with HIV.
Dovato (dolutegravir/lamivudine) is the second approved two-antiretroviral regimen.
In clinical trials, the single-tablet regimen of Tivicay (dolutegravir) and Epivir (lamivudine) was as effective as a three-drug treatment.
Full 48-week results comparing dolutegravir plus lamivudine with a three-drug combo were presented at the International AIDS Conference.
The combo of dolutegravir and lamivudine controlled HIV as well as a triple-drug combo of dolutegravir plus Truvada.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.